Given the therapeutic implications, routine testing for MPN-driver mutations, JAK2 V617F, CALR, and MPL sequentially, should be performed in patients with splanchnic vein thrombosis, particularly in those without obvious provoking factors, regardless of blood count abnormalities [65]. This evidence concerns the gene JAK2 and myeloproliferative disorder.